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Abstract
The detailed methylation status of CpG sites in the promoter region of hMSH2 gene has yet not
to be reported. We have mapped the complete methylation status of the hMSH2 promoter, a
region that contains 75 CpG sites, using bisulfite genomic sequencing in 60 primary colorectal
cancers. And the expression of hMSH2 was detected by immunohistochemistry. The
hypermethylation of hMSH2 was detected in 18.33% (11/60) of tumor tissues. The protein of
hMSH2 was detected in 41.67% (25/60) of tumor tissues. No hypermethylation of hMSH2 was
detected in normal tissues. The protein of hMSH2 was detected in all normal tissues. Our study
demonstrated that hMSH2 hypermethylation and protein expression were associated with the
development of colorectal cancer.
Background
Methylation mapping is a particularly useful method for
determining the methylation profile of a gene[1], and for
some genes, including RASSF1A [2], E-cadherin [3],
p16[4], cyclooxygenase-2 [5] and the estrogen receptor
[6], the methylation pattern of the promoter region has
been thoroughly examined. However, despite the impor-
tance of methylation mapping in investigating profiles of
the promoter region of hMSH2 have yet to be examined.
Hence, to examine the methylation profiles of 75 CpG
sites in the 979-bp promoter region of the human hMSH2
gene, we performed conversion-specific bisulfite genomic
sequencing in 60 primary colorectal cancers. Furthermore,




Primary colon cancer tissue was obtained by surgical
resection from 60 patients (37 male, 23 female; median
age of 56 years, range 24–83 years) with sporadic colorec-
tal cancer. All of these patients corresponding non cancer
colon tissue was also obtained from a tumour-free loca-
tion, which was at least 5 cm distant from the tumour and
which was confirmed to be without any tumour cell infil-
tration by histology. Immediately after surgery, tissue
samples were put in liquid nitrogen and stored at -80°C
until use.
DNA extraction and bisulfite genomic sequencing
Genomic DNA of all samples was extracted from the tis-
sues using QIAamp® DNA Mini Kit (Qiagen, Inc., Ger-
many), according to the manufacturer's instructions.
Bisulfite modification of the genomic DNA was carried
out using DNA Modification Kit (ZYMO Research, USA).
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The modified DNA was amplified by PCR, using the two
sets of primers shown in Table 1. The primers were
designed for the hMSH2 promoter and exon1 (GenBank
accession number U23824, U41206) [25] using Meth-
Primer, a program for designing bisulfite-conversion-
based methylation PCR primers [26]. These primers were
specific for the modified DNA, but did not contain any
CpG sites in their sequence, and therefore both methyl-
ated and unmethylated DNA can be amplified by the
same primer sets. Each PCR mixture contained genomic
DNA, 1.25 units TaKaRa Ex Taq HS (Takara, Tokyo,
Japan), 1X Ex Taq buffer, 2 mM deoxynucleotide triphos-
phate mixture, and 50 pmol sense and antisense primers
in a volume of 25 μl. The PCR conditions were 94°C for 5
min, 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C
for 60 s, With a final extension reaction at 72°C for 5 min.
The PCR products were sequenced on an ABI automated
sequencer 3100 with Dye terminators (ABI, USA).
Immunohistochemistry
Deparaffinized serial sections were cut at 4 μm for immu-
nohistochemistry and placed on Superfrost Plus glass
slides. Prior to immunostaining, sections were deparaffin-
ized in xylene and rehydrated in an alcohol series. Immu-
nostaining was performed with hMSH2 antibody
(CALBIOCHEM, USA).
Incubation with the primary antibodies was performed in
a moist chamber at 37°C for 1 h. After incubation with
the secondary antibody (30 min, room temperature;
Dako, Denmark). Immunohistochemical staining was
performed using EnVision™ Detection Kit(Dako, Den-
mark). Evaluation of the slides was performed by an expe-
rienced pathologist who was blinded to the results of the
methylation analysis.
Statistical analysis
Statistical analysis was performed using a X2 test for com-
parison of the overall methylation level. A probability of
P < 0.05 was considered to be statistically significant.
Results
Analysis of hMSH2 methylation
Bisulfite DNA sequencing was carried out to assess the
extent of CpG island methylation in the hMSH2 gene pro-
moter in carcinoma cells and normal colonic cells. Results
was shown in Table 2. Examples of such sequencing are
presented in Fig 1: note that after bisulfite treatment,
unmethylated cytosine was converted to thymine. The
hypermethylation of hMSH2 was detected in 18.33% (11/
60) of tumor tissues. No hypermethylation of hMSH2 was
detected in normal tissues.
Immunohistochemistry
The results of immunohistochemistry are shown in Fig. 2
and Fig. 3. The protein of hMSH2 was detected in 41.67%
(25/60) of tumor tissues. The protein of hMSH2 was
detected in all normal tissues.
Discussion
Methylation mapping is one of the most useful methods
available for determination of the methylation profiles of
a promoter region. In the present study, we were able to
achieve complete methylation mapping of the hMSH2
promoter region, using primers obtained from Meth-
primer software. This program is useful for designing spe-
cific PCR primers that can perform selective amplification
of modified DNA only [7].
We results showed: the hypermethylation of hMSH2 was
detected in 18.33% (11/60) of tumor tissues. The protein
of hMSH2 was detected in 41.67% (25/60) of tumor tis-
sues. No hypermethylation of hMSH2 was detected in
normal tissues. The protein of hMSH2 was detected in all
normal tissues. Our study demonstrated that hMSH2
hypermethylation and protein expression were associated
with the development of colorectal cancer.
In studies using bisulfite genomic sequencing and meth-
ylation specific PCR, contamination with stroma may
yield false positive results. Thus, to eliminate stromal cells
from the samples, studies using microdissected specimens
are recommended for future studies.
In conclusion, this study has clarified the detailed methyl-
ation status of wide area of the hMSH2 promoter region
in colon cancer. The results suggest that methylation of
certain CpG sites may play a particularly important role in
the regulation of hMSH2 gene transcription. Primers used
for future MSP analysis can be designed on the basis of
these detailed sequencing data, and hence our mapping
Table 1: Primers used for bisulfite genomic sequencing
Name Sequence Number of CpG sites in PCR product Size (bp)
MSH2-1F AGGGGTTTTAAGTTTTGTAGTTGAG 46 520
MSH2-1R CCATATACTTAATCACCCCCTAAAT
MSH2-2F TTAAGATTTAGGGGGTGATTAAGTA 29 459
MSH2-2R TATCATAAAAAAATCTCCTAAACCCJournal of Carcinogenesis 2006, 5:22 http://www.carcinogenesis.com/content/5/1/22
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Table 2: methylation of hMSH2
Group Cases Methylation Unmethylation P Value
Age
< 50 17 3 14
≥50 43 8 35 P > 0.05
Sex
Male 37 7 30
Female 23 4 19 P > 0.05
Position
Colon cancer 28 5 23
Rectal cancer 32 6 26 P > 0.05
Ducks stage
A,B 42 2 40
C,D 18 9 9 P < 0.01
Histodifferentiation degree
Well 13 1 12
Moderate, poor 47 10 37 P < 0.01
Lymph node and distant 
metastasis
Yes 18 8 10
NO 42 3 39 P < 0.05
Examples of bisulfite genomic sequencing chromatography Figure 1
Examples of bisulfite genomic sequencing chromatography. DNA was amplified and sequenced using each primer set 
on an ABI automated sequencer with dye terminators. After bisulfite treatment, unmethylated cytosine was converted to 
thymine. TG is a partial methylation point.
Normal cells showed stable expression Figure 2
Normal cells showed stable expression.
cancer cells did not show immunoreactivity Figure 3
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data provide an important basis for further studies of
methylation-regulated hMSH2 inactivation.
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